Back to search
FDAFDA · Food and drugs·Recall number D-002-2014

Oxcarbazepine Oral Suspension, 300 mg/5 mL, 250 mL bottle, Rx only, Boehringer Ingelheim, Roxane Laboratories, Inc. Columbus, Ohio 43216, NDC 0054-0199-59

Published November 27, 2013 · Recall initiated: April 3, 2013

Summary

FDA records drug Class II recall D-002-2014, published November 27, 2013 and initiated April 3, 2013. Recalling firm: Boehringer Ingelheim Roxane Inc; Status: Terminated; Reported quantity: 10,267 bottles; Lot: Lot # 161304B, Exp. OCT 2013. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Resuspension Problems: Recalled lot did not meet resuspendability requirements.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Boehringer Ingelheim Roxane Inc
Distributor
Nationwide
Lot
Lot # 161304B, Exp. OCT 2013
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Oxcarbazepine Oral Suspension, 300 mg/5 mL, 250 mL bottle, Rx only, Boehringer Ingelheim, Roxane Laboratories, Inc. Columbus, Ohio 43216, NDC 0054-0199-59 recalled?

Yes. FDA published recall D-002-2014 on November 27, 2013. Reported hazard: Resuspension Problems: Recalled lot did not meet resuspendability requirements.

What should I do if I have this product?

Voluntary: Firm initiated · Letter